Skip to content
ePORE Therapy Logo
  • Platform
    • ePORE® therapy Technology
    • ePORE® therapy Treats
    • Benefits of ePORE® therapy
    • EndoVE®
    • CUTIS
  • Gastrointestinal Therapy
    • Clinicians
    • Patient Information
  • Skin Therapy
    • Clinicians
    • Patient Information
  • News
  • About Mirai
  • Contact
  • Platform
    • ePORE® therapy Technology
    • ePORE® therapy Treats
    • Benefits of ePORE® therapy
    • EndoVE®
    • CUTIS
  • Gastrointestinal Therapy
    • Clinicians
    • Patient Information
  • Skin Therapy
    • Clinicians
    • Patient Information
  • News
  • About Mirai
  • Contact

Author: admin

Filter by Topic
Filter by Topic
Digestive Disease Week 2024
Read More
22.08.2024
MIRAI MEDICAL supports the British Society for Dermatological Surgery (BSDS)
Read More
22.08.2024
Celebrating 60 Years of the European Society of Gastrointestinal Endoscopy
Read More
22.08.2024
MedTech Innovator Crowns Mirai Medical Among Top Innovators for 2023
Read More
28.11.2023
Mirai Medical attends the Australasian Melanoma Conference (AMC) 2023
Read More
24.03.2023
Mirai Medical treats the first skin cancer patient in Australia with ePORE® therapy
Read More
17.03.2023
The first clinical paper published using electroporation in conjunction with calcium for the treatment of colorectal cancer
Read More
13.02.2023
First live surgery demonstration of Mirai Medical’s ePORE® therapy for the treatment of gastrointestinal cancers
Read More
2.11.2022
Mirai Medical appoints Paraic Curtis to the board
Read More
30.06.2022
First patient with oesophageal cancer is treated in Germany using ePORE® therapy with EndoVE®
Read More
16.06.2022

Contact Us

By clicking send, you confirm you have read and agreed to Mirai Medical's Privacy Policy.
Twitter Linkedin-in Youtube
ePORE Therapy White Logo
Address:
Mirai Medical
Unit 5, Howley Court
Oranmore
Galway
Ireland
Email:
info@mirai-medical.com
Mirai Medical logo white
© Copyright 2025 MIRAI MEDICAL. All Rights Reserved.
Privacy & Cookies
ePORE® therapy, EndoVE® and CUTIS are approved for commercialisation in the European Union, United Kingdom and Australia. ePORE® therapy, EndoVE® and CUTIS are not cleared by FDA for commercialisation in the USA.
WEEE Ireland Certificate of Registration MIR 100
PRL Registration Number: IE 02581 WB
Website by Proactive Design & Marketing